Denton and Reddish MP, Andrew Gwynne, has backed Cancer52 and their campaign for individuals affected by rare and less common cancers, which account for more than half of all cancer deaths in the UK.
Cancer52 and Novartis Oncology are working together to raise awareness of rare and less common cancers. 54 per cent of UK cancer deaths are from rare and less common cancers but policy to improve outcomes for patients has focused on the ‘big four’ cancers– lung, bowel, prostate and breast.
The group which represents 90 predominantly small cancer charities believes that there must be parity between rare and less common cancers and the ‘big four’ in relation to early diagnosis as well as access to treatment – without this, outcomes for patients with these cancers are unlikely to improve.
Current data shows that 46% of cancers diagnosed are rare and less common cancers, yet they account for 54% of cancer deaths.
Andrew Gwynne said:
“I think it’s absolutely vital to raise awareness of rare and less common cancers, especially considering that over half of all deaths associated with cancer are attributed to less common forms.
“If we begin to treat these rarer forms of cancer as seriously as we have done with lung, bowel and breast cancer then we can really start to see improved outcomes across the spectrum.”